Lithium has a reputation problem that has nothing to do with whether it works. Ask a room of prescribers why they hesitate to start it and you will hear the same answer: the kidneys. That worry is rooted in real data, and it has quietly pushed a drug with the best evidence in bipolar disorder to the back of many formularies.
A 2026 expert opinion paper in the International Journal of Bipolar Disorders takes that worry head on. Strandhave and colleagues, writing on behalf of a long list of lithium researchers that includes names from the International Group for the Study of Lithium-Treated Patients, reviewed what we know about lithium and renal function and built a management algorithm around it. The Psychopharmacology Institute summarized the guidance in its August 2026 update, and the message for anyone writing lithium prescriptions is fairly plain: the kidney risk is real, it is manageable, and most of the management happens in how you run your practice, not in the prescription itself.
If you are a PMHNP with your own panel, that last part is the interesting one.
What the paper actually says
The authors start from a position that may surprise clinicians who were trained to fear the drug. Lithium remains the reference standard for mood stabilization in recurrent mood disorders, with strong evidence for reducing both recurrence and suicide. Mild to moderate chronic kidney disease is a recognized risk of long-term treatment. But newer studies report fewer severe outcomes, such as end-stage kidney disease requiring dialysis or transplant, than the older literature did, particularly when patients are monitored properly.
That second point matters. Much of the older fear came from cohorts treated in an era of higher serum levels, less frequent labs, and more episodes of toxicity. The paper names the factors that seem to drive harm: a rapid early decline in glomerular filtration rate, starting treatment young, cumulative lithium exposure, higher average serum levels, and episodes of toxicity. Notice how many of those are things a prescriber can influence. Level targets, lab frequency, and how quickly you catch a bad week of dehydration are practice decisions.
The paper also describes two distinct kidney effects that are worth keeping straight. One is resistance to arginine vasopressin, which shows up as polyuria, nocturia, and nighttime thirst. Patients often mistake it for diabetes or a bladder problem. The other is chronic interstitial nephritis, the slower structural injury that drives the eGFR decline. They need different responses, and the first is often the earlier clue.

The numbers worth writing on a sticky note
According to the Psychopharmacology Institute’s summary of the guidance, the relationship between average serum level and chronic kidney disease is steep. In the data it cites, mean levels of 0.30 to 0.59 mmol/L were not tied to excess CKD, while 0.60 to 0.79 was associated with roughly a threefold increase and 0.80 to 0.99 with a bit more than fourfold. The practical read is to aim below 0.80 mmol/L, dosed once daily, and to treat that as a ceiling for maintenance rather than a goal.
I would hold those multipliers loosely. They come from observational data and a secondary summary, and your patient with three failed trials and a 0.85 who has been stable for eleven years is a different conversation than a new start. What does not change is the direction: lower sustained exposure means less renal risk, and the people who benefit most from lithium often do well at levels lower than the ones we were taught to chase.
The suggested monitoring is not exotic. Baseline and then once or twice a year: renal function, electrolytes, calcium, thyroid and parathyroid function, and an ECG. Lithium levels about every three months. At each visit, ask about thirst, urine volume, and getting up at night to void. Refer to nephrology if eGFR drops below 60.
On treatment of vasopressin resistance, the guidance points to amiloride as the off-label option with support behind it. Spironolactone is not effective for this. Thiazides can reduce urine output but can also push lithium levels up and disturb electrolytes, so use them with care.
Do not stop reflexively
This is the part I would underline for anyone who has ever panicked over a falling eGFR. The paper cautions against stopping lithium just because renal function is drifting down. Around an eGFR of 30 to 40, the decline often continues even after withdrawal, which clinicians sometimes call the point of no return. So the leverage is early. Getting the dose and levels right in the first years does far more for the kidney than a late discontinuation does.
The related point is that switching to valproate in the name of renal protection is not supported. You may be trading a manageable risk for a different set of problems, including teratogenic and metabolic ones, in a patient who was stable. If you do decide that lithium has to go, the summary recommends tapering over at least three months while starting an alternative, because abrupt discontinuation carries its own relapse risk.

Why this is a private practice problem, not just a prescribing problem
In a hospital system, lab recall happens in the background. A pharmacist, a nephrology consult, or an automated best-practice alert nudges someone when the creatinine is due. In a solo or small group practice there is nobody behind you. The monitoring schedule in this guidance only works if you build the machinery for it, and that machinery is yours to design.
Start with the tracking. Every lithium patient needs a next-labs-due date that lives somewhere other than your memory. In most EHRs that means a recurring task tied to the three-month level and the yearly panel. If yours cannot do that, use a tracking sheet inside a HIPAA-compliant environment, never a consumer tool.
Then think about who orders and who reviews. Many PMHNPs in private practice quietly depend on the patient’s primary care office to order renal labs and forward results. That works until it does not. A patient changes PCPs, a result goes to the wrong fax, or a visit gets skipped. Decide as a practice policy that you order the lithium labs yourself, you review them, and you document the review. It is more work up front and far less stressful than finding out a value has been missing for fourteen months.
The collaborating physician conversation belongs here too, depending on your state. If you practice under a collaborative agreement, lithium is a good example of a medication to name specifically in your protocols: monitoring intervals, the eGFR threshold that triggers a referral, and what you do with a rising level. A written protocol turns a vague sense of oversight into something you can actually point to.
Building an intake that surfaces the risks early
The paper lists dehydration episodes and toxicity as drivers of damage, which means patient education is a clinical intervention, not a handout. The things I would cover at the first prescribing visit and revisit regularly are simple. Tell the patient to call you if they have a stomach bug with vomiting or diarrhea, heavy sweating from illness or heat, or a plan to start an NSAID like ibuprofen or naproxen. Ask them to flag any new blood pressure medication, especially an ACE inhibitor, an ARB, or a thiazide, because those can raise lithium levels.
Put that guidance in writing, in language that does not read like a package insert, and give a phone number that gets answered. A patient who knows to call when they are throwing up on a Tuesday is a patient whose level does not reach 1.5 on Thursday.

The business case for being the practice that does lithium well
I do not want to make lithium sound like a revenue strategy, because the clinical reasons are strong enough on their own. But it is worth noticing what the current environment looks like for people with bipolar disorder who need a prescriber. Many clinicians avoid lithium because of the monitoring burden. Patients on it often get passed between providers or quietly switched to a second-generation antipsychotic they did not ask for. A practice with a clear lithium pathway, one that explains the monitoring plan, orders its own labs, and treats the kidney question with specificity instead of fear, is offering something that is harder to find than it should be.
That can show up in how you describe your practice. If your website says you manage bipolar disorder, consider saying more than that. A short page explaining how you approach long-term mood stabilization, including that you monitor kidney, thyroid, and calcium on a set schedule, signals competence to patients and to referring PCPs who are tired of chasing labs. Describe the process, not promised outcomes.
Referral relationships are another angle. A primary care physician who knows you will order the labs, send the results, and call about an eGFR trend is a physician who will keep sending you complicated patients. Nephrology is the same story in reverse. Establish a contact before you need one, so an eGFR of 58 results in a quick call rather than a month of phone tag.
Where I would be careful
A few caveats are worth stating plainly. The Strandhave paper is an expert opinion and management algorithm, not a randomized trial. It synthesizes epidemiologic, observational, and experimental work, and it says more research and clinician education are needed. The serum level thresholds and fold-increases I mentioned come from observational associations. They do not prove that lowering a given patient’s level by 0.1 will protect that patient’s kidneys.
If you build a protocol on specific cutoffs, read the paper itself (DOI 10.1186/s40345-026-00423-z) and check the details against your state’s scope of practice rules, your collaborative agreement if you have one, and your malpractice carrier’s expectations.
And individualize. A 24-year-old starting lithium after a first manic episode and a 61-year-old with hypertension, diabetes, and an eGFR of 52 are not the same patient, and no algorithm replaces thinking about which one is in front of you.
What to do this month
You do not need to overhaul your practice to act on this. Pull a list of every active lithium patient. For each one, find the date and result of the last level, the last eGFR, and the last thyroid and calcium. Anyone overdue gets a lab order this week. Anyone running a level above 0.80 gets a deliberate decision documented in the chart: either a reason to stay there, or a plan to come down. Anyone with polyuria or nighttime thirst gets asked about it directly.
Then fix the system so you do not have to repeat the audit next year. A recurring task, a written protocol, and a patient handout cover most of it.
If you are building a practice and trying to decide how much risk you can responsibly carry, this is a decent illustration of how the work actually goes. The clinical knowledge is the smaller piece. What separates a practice that prescribes lithium confidently from one that avoids it is mostly infrastructure.
For more practical guidance on running a psychiatric private practice, from collaborative agreements and compliance to the systems that keep patients safe, explore the rest of the library at pmhnpwebsite.com.
